You can visit an educational portal for a more front row seat to what is being discussed and workshoped at a variety of conferences. Let's face it--it isn't always practical to travel to meetings or conferences. The backlog of blog worthy topics seemed like a great opportunity to introduce deeper dives in a new digital media discussion forum. Lessons and discussions will launch soon (and individually). You can sign-up for information about releases here.
My intention is to share summaries and highlights within the blog but I don't assume we all have equal exposure (or interest) in all topics. Many of the conferences I attend provide unique opportunities for specific skill development or benchmarks within topics of health policy, HEOR, clinical science, research, or writing about medicine. If you want to roll up your sleeves and add a few new skills to your toolbox, maybe a deeper dive is just what you need.
ISPOR 2016...to be continued
The plenary sessions opened Monday morning with advances and forward thinking objectives from the 20,000 global membership--reaffirming accomplishments and the mission of ISPOR. Guided as a member led society with a role as strategic innovator, collaborator, influencer, and convener--if you work in health economics, policy, or science you have seen remarkable advances in technology, breakthroughs in medical devices, combined with multiple stakeholder interest in evidence, cost, policy, and value frameworks. Our dynamic role in healthcare emphasizes the importance of possessing a solid foundation in health economics and pharmacoeconomics.
Not everyone needs to be a health economist or health policy expert to appreciate theoretical frameworks addressing these important issues. ISPOR stimulates innovation through dialogue, deliberation on value-frameworks, networking and a variety of stakeholder perspectives integral to sound decision making.
Last summer the 21st Century Cures Act was passed with bipartisan support. Eleanor M. Perfecto, PhD, MS from the National Health Council presented a few highlights. You can click here for more details from H.R.6. I get it. We are all busy but I think we can also pause and examine facts prior to passing around partially informed opinions that can distort or mislead.
Important narratives are lost in the noise. Healthcare and innovation is at a crossroads. How do we balance patient safety and unmet medical need? There are valid arguments regarding FDA approvals based on less rigorous data but how do we then consider patient outcomes and experiences--real world evidence? Non-traditional study designs are limited to correlation but how should we balance innovative approaches with efficacy and efficiency. And perhaps most importantly, how do we select valid surrogate measures to speed drug approval for patients most in need?
I hope you will follow along as the conversation continues...
Thoughtful discussions about content development and outcomes analytics that apply the principles and frameworks of health policy and economics to persistent and perplexing health and health care problems...